Efficacy

Alunbrig (brigatinib) Efficacy in Lung Cancer

Alunbrig (brigatinib) is a targeted therapy approved for the treatment of non-small cell lung cancer (NSCLC) with a specific genetic alteration known as anaplastic lymphoma kinase (ALK) positive. The efficacy of Alunbrig in treating ALK-positive NSCLC has been demonstrated in several clinical trials. Notably, the ALTA-1L trial, which compared brigatinib to crizotinib in ALK-positive NSCLC patients who had not received prior ALK inhibitor therapy, showed that brigatinib significantly improved progression-free survival. Patients treated with brigatinib experienced a median progression-free survival of 24 months compared to 11 months for those on crizotinib, indicating a strong efficacy in delaying disease progression.

In addition to the ALTA-1L trial, the efficacy of Alunbrig has been observed in patients who have progressed on crizotinib, which is another ALK inhibitor. In these cases, brigatinib has demonstrated a high overall response rate, with a significant proportion of patients achieving partial or complete responses. This suggests that Alunbrig can be effective in patients who have developed resistance to first-line ALK inhibitors.

Enhertu (fam-trastuzumab deruxtecan-nxki) Efficacy in Lung Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate that targets HER2, a protein that can promote the growth of cancer cells. While traditionally associated with breast cancer, HER2 mutations are also present in a subset of non-small cell lung cancers. The efficacy of Enhertu in HER2-mutant NSCLC was evaluated in a phase 2 trial, where it demonstrated promising results. Patients with HER2-mutant NSCLC who were treated with Enhertu showed a notable response rate, with a significant number of patients experiencing tumor shrinkage.

Moreover, the duration of response and progression-free survival in patients treated with Enhertu were considered clinically meaningful, offering a new therapeutic option for this specific group of lung cancer patients. The data from the trial support the use of Enhertu in the treatment of patients with NSCLC who have HER2 mutations and have received prior therapies. The drug's efficacy in this setting provides an important advancement for a group of patients with limited treatment options.